Inventor
HYND GEORGE
GB40 patents
⚠️ This page may combine multiple inventors who share the name “HYND GEORGE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
JANSSEN PHARMACEUTICA NV
13 patentsUS9643964B2May 9, 2017
3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer
JANSSEN PHARMACEUTICA NV9 citations83
US11236084B2Feb 1, 2022
Substituted azaindoline derivatives as NIK inhibitors
JANSSEN PHARMACEUTICA NV0 citations50
US11186589B2Nov 30, 2021
Cyanoindoline derivatives as NIK inhibitors
JANSSEN PHARMACEUTICA NV0 citations50
US11180487B2Nov 23, 2021
Substituted cyanoindoline derivatives as NIK inhibitors
JANSSEN PHARMACEUTICA NV0 citations50
US11136311B2Oct 5, 2021
Heteroaromatic derivatives as NIK inhibitors
JANSSEN PHARMACEUTICA NV0 citations50
US11001569B2May 11, 2021
6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
JANSSEN PHARMACEUTICA NV0 citations50
US10822342B2Nov 3, 2020
Pyrazolopyrimidine derivatives as NIK inhibitors
JANSSEN PHARMACEUTICA NV0 citations50
US10221180B2Mar 5, 2019
Pyrazolopyrimidine derivatives as NIK inhibitors
JANSSEN PHARMACEUTICA NV0 citations50
US10005773B2Jun 26, 2018
1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors
JANSSEN PHARMACEUTICA NV0 citations40
US10005776B2Jun 26, 2018
Compounds as NIK inhibitors
JANSSEN PHARMACEUTICA NV0 citations40
US10323045B2Jun 18, 2019
Thienopyrimidine derivatives as NIK inhibitors
JANSSEN PHARMACEUTICA NV0 citations39
US9981963B2May 29, 2018
3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors
JANSSEN PHARMACEUTICA NV0 citations39
US9981962B2May 29, 2018
Pyrazole derivatives as NIK inhibitors
JANSSEN PHARMACEUTICA NV0 citations38
ASTERAND UK LTD
9 patentsUS7803841B2Sep 28, 2010
EP2 receptor agonists
ASTERAND UK LTD11 citations82
US7662839B2Feb 16, 2010
EP2 receptor agonists
ASTERAND UK LTD7 citations72
US7569602B2Aug 4, 2009
Furan derivatives as EP4 receptor antagonists
ASTERAND UK LTD6 citations72
US7417068B2Aug 26, 2008
EP4 receptor antagonists
ASTERAND UK LTD8 citations72
US7196089B2Mar 27, 2007
EP4 receptor antagonists
ASTERAND UK LTD8 citations71
US7528157B2May 5, 2009
EP4 receptor antagonists
ASTERAND UK LTD3 citations60
US7507754B2Mar 24, 2009
EP4 receptor antagonists
ASTERAND UK LTD3 citations60
US7858644B2Dec 28, 2010
EP4 receptor antagonists
ASTERAND UK LTD0 citations50
US7429607B2Sep 30, 2008
5-HT2B receptor antagonists
ASTERAND UK LTD1 citations44
CANCER RESEARCH TECH LTD
6 patentsUS11352361B2Jun 7, 2022
Compounds useful as RET inhibitors
CANCER RESEARCH TECH LTD3 citations71
US10954241B2Mar 23, 2021
Heterocyclic compounds as ret kinase inhibitors
CANCER RESEARCH TECH LTD3 citations71
US10844067B2Nov 24, 2020
Heterocyclic compounds as RET kinase inhibitors
CANCER RESEARCH TECH LTD4 citations71
US11680068B2Jun 20, 2023
Compounds useful as RET inhibitors
CANCER RESEARCH TECH LTD1 citations61
US11661423B2May 30, 2023
Heterocyclic compounds as RET kinase inhibitors
CANCER RESEARCH TECH LTD1 citations60
US11548896B2Jan 10, 2023
Heterocyclic compounds as RET kinase inhibitors
CANCER RESEARCH TECH LTD1 citations60